AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04399538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet
Study NCT02126436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
Study NCT02126436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
Study NCT04399538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet
Study NCT04399538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT02657070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement-Induced Movement Therapy (RIMT)
Description: 6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
Study NCT02657070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR-based motor rehabilitation in RGS without augmented feedback
Description: 6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Pre-operative assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Post-operative day 3 assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing.
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Post-operative week 4-6 assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing.
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Post-operative 3 month assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing.
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Pre-operative 6 month assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing.
Study NCT04388930 — intervention group
Intervention type: OTHER
Intervention: Post-operative month 12 recipient assessment - blood, urine, & faecal sample
Description: Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing.
Study NCT02372058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BiliCare
Description: Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device
Study NCT02339701 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT
Study NCT02339701 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Study NCT03108963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine and Metformin
Description: L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
Study NCT03108963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
Study NCT00515398 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Ex vivo administration of AT2220
Study NCT01839968 — intervention group
Intervention type: OTHER
Intervention: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma
Study NCT02359591 — intervention group
Intervention type: OTHER
Intervention: text-based or multimedia
Description: subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
Study NCT04131959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb 300 mL device
Description: Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
Study NCT03050398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: ribociclib + letrozole
Study NCT03050398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: ribociclib + letrozole
Study NCT00624039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UBM with pilocarpine in presbyopia
Description: ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
Study NCT02411344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: * Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).
Study NCT01627795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D and Oshadi R
Description: anti cancer agents
Study NCT00908596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid disodium (Primovist, BAY86-4873)
Description: Primovist/Eovist in approved indications at approved dosages
Study NCT04839432 — intervention group
Intervention type: BEHAVIORAL
Intervention: implementation of albumin solution in the priming of the cardiopulmonary bypass machine
Description: In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
Study NCT01500655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional nerve block
Description: a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
Study NCT04022577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Therapy
Description: Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
Study NCT04022577 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: The control group received routine care
Study NCT00510146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
Study NCT01500655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
Study NCT04465084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Case
Description: Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
Study NCT04465084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Withness
Description: Experimental language tasks MRI
Study NCT03048071 — intervention group
Intervention type: OTHER
Intervention: Data collection within medical files
Description: Data collection within medical files
Study NCT03581617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NK cell analysis
Description: We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry
Study NCT03581617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Herpesvirus detection
Description: Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
Study NCT03581617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sHLA-G analysis
Description: sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
Study NCT03581617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-G 14bp INS/DEL typing
Description: Genomic DNA will be genotyped by RealTime PCR
Study NCT03581617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sHLA-E analysis
Description: sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
Study NCT00386230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Short (mother)-Short (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
Study NCT00386230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Short (mother)-Long (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
Study NCT00386230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Long (mother)-Short (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
Study NCT00386230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZDV Long (mother)-Long (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
Study NCT03627650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipofilling/ fat grafting
Description: liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
Study NCT03627650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placebo injection
Study NCT00565097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00565097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study NCT03447964 — intervention group
Intervention type: OTHER
Intervention: dosing of sphingolipids
Description: - Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Study NCT00510146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, oral, once daily at bedtime, 6 weeks
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg d0
Study NCT02242370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan
Study NCT02242370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan
Study NCT02855177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as suspension administered every 8 hours, with food
Study NCT02855177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: 500 mg suspension administered every 8 hours, with food
Study NCT02493530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established.
Study NCT02493530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Study NCT02485756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handout
Description: Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
Study NCT04183569 — intervention group
Intervention type: OTHER
Intervention: Sequencing RNA.
Description: RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
Study NCT01441245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide infusion
Description: Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
Study NCT01210014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc sulphate 220mg/day in one dosage
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
Study NCT01210014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo: one dosage
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02488967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 d0
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 d1
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 d1
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 (maximum 2mg) d1
Study NCT04181489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg/m2 d1-5
Study NCT02418962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
Study NCT02418962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride solution for injection
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02488967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03337048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: SpeediCath is a standard intermittent catheter that is on the market.
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: continuous infusion 0.4 mcg/kg/min
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: bolus injection
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: bolus injection for 30 sec 1.0 mg/kg
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (for remifentanil)
Description: normal saline mimic diluted remifentanil
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for midazolam)
Description: normal saline mimic to midazolam injection
Study NCT01693185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for meperidine)
Description: normal saline mimic meperidine injection
Study NCT03079973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3073 (calcipotriene 0.005%)
Description: Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
Study NCT03079973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of P-3073
Description: Once daily for 24 weeks.
Study NCT02283580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single limb
Description: Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise.